ライフサイエンスコーパス: cardiac amyloidosis

1 l, hypertension, dilated cardiomyopathy, and cardiac amyloidosis).

2 dial biopsy because of clinical suspicion of cardiac amyloidosis.

3 out the prognostic value of CV-IB in primary cardiac amyloidosis.

4 There is no muscle blood vessel or cardiac amyloidosis.

5 as both sporadic inclusion body myositis and cardiac amyloidosis.

6 be a useful predictor of clinical outcome in cardiac amyloidosis.

7 edictor of clinical outcome in patients with cardiac amyloidosis.

8 myocardial performance in the assessment of cardiac amyloidosis.

9 t chain amyloidosis and other rarer forms of cardiac amyloidosis.

10 n or when there is a suspicion of associated cardiac amyloidosis.

11 ss, such as hypertrophy, cardiomyopathy, and cardiac amyloidosis.

12 ing role in the evaluation and management of cardiac amyloidosis.

13 cintigraphy scan assessing for transthyretin cardiac amyloidosis.

14 ns with apolipoprotein E, and the analogy of cardiac amyloidosis.

15 on, fibrosis, thrombosis, calcification, and cardiac amyloidosis.

16 re, difficult to diagnose hereditary form of cardiac amyloidosis.

17 agnosed with hypertrophic cardiomyopathy and cardiac amyloidosis.

18 vel approaches for the diagnostic imaging of cardiac amyloidosis.

19 reening strategies for variant transthyretin cardiac amyloidosis.

20 g (ML) algorithm to identify and distinguish cardiac amyloidosis.

21 ng has been implicated in the development of cardiac amyloidosis.

22 dalities in both ischaemic heart disease and cardiac amyloidosis.

23 alence and incidence of hospitalizations for cardiac amyloidosis.

24 andard for diagnosis and characterization of cardiac amyloidosis.

25 ore than 0.96 for diagnosis of transthyretin cardiac amyloidosis.

26 ility of (18)F-florbetaben PET in diagnosing cardiac amyloidosis.

27 ent determinant of myocardial dysfunction in cardiac amyloidosis.

28 ients with symptomatic heart failure from AL cardiac amyloidosis.

29 with worse survival among patients with ATTR cardiac amyloidosis.

30 9m PYP cardiac imaging for detection of ATTR cardiac amyloidosis.

31 atients (26.7%) with COVID-19 had underlying cardiac amyloidosis.

32 ty in patients with amyloid light-chain (AL) cardiac amyloidosis.

33 ility to overcome poor prognosis of advanced cardiac amyloidosis.

34 ned reliably by PSIR and represents advanced cardiac amyloidosis.

35 t-chain amyloidosis are the 2 main causes of cardiac amyloidosis.

36 protinin was found to be useful in detecting cardiac amyloidosis.

37 e curve 0.992, P<0.0001 for identifying ATTR cardiac amyloidosis.

38 endent validation set comprising 41 cases of cardiac amyloidosis.

39 cy of intracardiac thrombosis was present in cardiac amyloidosis.

40 cement CMR was performed in 30 patients with cardiac amyloidosis.

41 n models that predict the log-odds of having cardiac amyloidosis.

42 1.71 [1.61, 1.91]; HFpEF, 1.66 [1.44, 1.89]; cardiac amyloidosis, 1.30 [1.16, 1.53]; P<0.001).

43 ause of heart failure in Afro-Caribbeans was cardiac amyloidosis (11.4%).

44 6 patients (85% hypertensive; 61% males; 14% cardiac amyloidosis), 27 (31%) patients died during the

45 TTR cardiac amyloidosis and 50 with non-ATTR cardiac amyloidosis [34 with AL amyloidosis and 16 with

46 A total of 116 autopsy or explanted cases of cardiac amyloidosis (55 AL and 61 other type) were ident

47 s with HFpEF (+4.4% [0.5, 6.4]; P=0.002) and cardiac amyloidosis (+6.4% [3.3, 10.0]; P=0.004), which

48 In patients with suspected cardiac amyloidosis, a combination of noninvasive parame

49 s an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and si

50 atients require histological confirmation of cardiac amyloidosis along with when and how to type amyl

51 Importance: Transthyretin cardiac amyloidosis (also known as ATTR cardiac amyloido

52 nsible for the increased frequency of senile cardiac amyloidosis among blacks.

53 The incidence and prevalence rates of cardiac amyloidosis among hospitalized patients have inc

54 to determine the incidence and prevalence of cardiac amyloidosis among Medicare beneficiaries from 20

55 The prevalence of transthyretin cardiac amyloidosis among older adults (often octogenari

56 eable percentage of elderly HF patients have cardiac amyloidosis, an HF precipitator.

57 P imaging of 171 participants (121 with ATTR cardiac amyloidosis and 50 with non-ATTR cardiac amyloid

58 ambda II germ-line genes was associated with cardiac amyloidosis and affected survival adversely.

59 in which 229 participants were evaluated for cardiac amyloidosis and also underwent Tc 99m PYP cardia

60 f specific therapies requires recognition of cardiac amyloidosis and appropriate characterization of

61 the management and outcomes in transthyretin cardiac amyloidosis and assess the risk of ageism.

62 e endomyocardial biopsy for the diagnosis of cardiac amyloidosis and conclude with a section on quant

63 patient demographics can accurately identify cardiac amyloidosis and differentiate subtypes.

64 78 whites over 60 years of age with isolated cardiac amyloidosis and from two control groups (228 cas

65 ccurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease.

66 eatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyopathy, whe

67 ardiac imaging as a diagnostic tool for ATTR cardiac amyloidosis and its association with survival in

68 P cardiac imaging distinguishes AL from ATTR cardiac amyloidosis and may be a simple, widely availabl

69 data for patients with transthyretin (ATTR) cardiac amyloidosis and NYHA class I-III symptoms at bas

70 espective of genotype) from patients with AL cardiac amyloidosis and patients with nonamyloid heart f

71 ter (CSMC) Advanced Heart Disease Clinic for cardiac amyloidosis and the Stanford Center for Inherite

72 lenge successful management of patients with cardiac amyloidosis and VT/VF.

73 HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ res

74 One participant died from cardiac amyloidosis, and one withdrew owing to progressi

75 ophic cardiomyopathy, stress cardiomyopathy, cardiac amyloidosis, and sarcoidosis.

76 FpEF, including hypertrophic cardiomyopathy, cardiac amyloidosis, and storage diseases, discussing th

77 ent VT/VF in more than half of patients with cardiac amyloidosis, and the reduction in VT/VF burden p

78 approaches to the diagnosis and treatment of cardiac amyloidosis are discussed, with particular refer

79 usions The incidence and prevalence rates of cardiac amyloidosis are higher than previously thought.

80 , 1.4 mm; 95% CI, 1.2-1.5 mm) and classified cardiac amyloidosis (area under the curve [AUC], 0.83) a

81 d 216 patients with histologically confirmed cardiac amyloidosis at a single center with electrocardi

82 mean age, 68+/-10 years; male sex, 91%) with cardiac amyloidosis (ATTR [transthyretin], n=16; light c

83 Transthyretin cardiac amyloidosis (ATTR CA) is increasingly recognized

84 Transthyretin cardiac amyloidosis (ATTR) is an underrecognized cause o

85 evere aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR) is increasingly recognized.

86 Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyo

87 c stenosis (AS) and transthyretin-associated cardiac amyloidosis (ATTR-CA) is an increasingly recogni

88 Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recogni

89 Transthyretin cardiac amyloidosis (ATTR-CA) is an overlooked cause of

90 Transthyretin cardiac amyloidosis (ATTR-CA) is an underdiagnosed but t

91 d to much greater awareness of transthyretin cardiac amyloidosis (ATTR-CA).

92 e medications in patients with transthyretin cardiac amyloidosis (ATTR-CA).

93 a are lacking in patients with transthyretin cardiac amyloidosis (ATTR-CA).

94 been suggested to discriminate transthyretin cardiac amyloidosis (ATTR-CM) from other causes of incre

95 Transthyretin cardiac amyloidosis (ATTR-CM) is an exemplar of precise

96 idosis (ATTRwt) and hereditary transthyretin cardiac amyloidosis (ATTRm).

97 development of both wild-type transthyretin cardiac amyloidosis (ATTRwt) and hereditary transthyreti

98 hese conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly being diagn

99 Wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly recognized

100 deep learning algorithm accurately detected cardiac amyloidosis (AUC, 0.79) and hypertrophic cardiom

101 hances our understanding of how cerebral and cardiac amyloidosis, autonomic dysfunction, and endocrin

102 is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying r

103 ) cardiac imaging noninvasively detects ATTR cardiac amyloidosis, but the accuracy of this technique

104 relevance of cardiac hemodynamic cutoffs in cardiac amyloidosis (CA) and its subtypes.

105 Patients with rare conditions such as cardiac amyloidosis (CA) are difficult to identify, give

106 myloid deposition in the heart, diagnosis of cardiac amyloidosis (CA) based on these conventional tec

107 on of amyloidosis and usually predates overt cardiac amyloidosis (CA) by several years.

108 Differentiation of cardiac amyloidosis (CA) from other causes of concentric

109 meters has been suggested for distinguishing cardiac amyloidosis (CA) from other causes of myocardial

110 Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains

111 unoglobulin amyloid light-chain (AL)-related cardiac amyloidosis (CA) has a worse prognosis than eith

112 The prevalence of cardiac amyloidosis (CA) in the general population and a

113 ence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) increases with age, and their a

114 Cardiac amyloidosis (CA) is a disease characterized by t

115 Background Cardiac amyloidosis (CA) is a disease of interstitial my

116 Cardiac amyloidosis (CA) is a set of amyloid diseases wi

117 Cardiac amyloidosis (CA) occurs when misfolded proteins

118 ents with suspected or histologically proven cardiac amyloidosis (CA) referred to specialist centres

119 ic societies have issued documents regarding cardiac amyloidosis (CA) to highlight the emerging clini

120 etween 2015 and 2023 and were diagnosed with cardiac amyloidosis (CA), myocarditis, dilated cardiomyo

121 e rare but increasingly recognized causes of cardiac amyloidosis (CA).

122 ar space, which is relevant to patients with cardiac amyloidosis (CA).

123 n (ATTR) and immunoglobulin light chain (AL) cardiac amyloidosis (CA).

124 cardiac thrombus are common in patients with cardiac amyloidosis (CA).

125 s (AS) are increasingly identified as having cardiac amyloidosis (CA).

126 s versus those with myocardial diseases (ie, cardiac amyloidosis [CA] and hypertrophic cardiomyopathy

127 Cardiac amyloidosis can be acquired in older individuals

128 Cardiac amyloidosis can be diagnostically challenging.

129 atic approach to the evaluation of suspected cardiac amyloidosis can impact the prognosis of patients

130 Cardiac amyloidosis can present as angina pectoris assoc

131 Clinical clues to promote recognition of cardiac amyloidosis, cardiac sarcoidosis, and cardiac he

132 which tailored interventions are available: cardiac amyloidosis, cardiac sarcoidosis, and cardiac he

133 tic resonance imaging findings suggestive of cardiac amyloidosis, cardiac scintigraphy can confirm th

134 Amyloid involvement of the heart (cardiac amyloidosis) carries the worst prognosis of any

135 In cardiac amyloidosis, CMR shows a characteristic pattern

136 Cardiac amyloidosis correlated with ECG abnormalities, a

137 ptal thickness is >1.98 cm, the diagnosis of cardiac amyloidosis could be made with a sensitivity of

138 Among patients with cardiac amyloidosis, CV-IB at the LV posterior wall is a

139 ollected from the French Referral Center for Cardiac Amyloidosis database (Hopital Henri Mondor, Cret

140 Since hereditary transthyretin cardiac amyloidosis demonstrates age-dependent anatomic

141 m pyrophosphate protocols for transthyretin cardiac amyloidosis diagnosis have variably used 1- and

142 c MRI trials for cardiomyopathies, including cardiac amyloidosis, dilated cardiomyopathy, hypertrophi

143 clear scintigraphy to diagnose transthyretin cardiac amyloidosis due to either variant or wild type t

144 he mechanisms underlying the pathogenesis of cardiac amyloidosis due to light chain (AL) or transthyr

145 ardiogram were associated with biopsy-proven cardiac amyloidosis (each p < 0.01).

146 phosphate scintigraphy and biopsy, ruled out cardiac amyloidosis, enabling transplant eligibility.

147 Conclusion Participants with cardiac amyloidosis exhibited an increase in extracellul

148 l presentation, diagnosis, and management of cardiac amyloidosis, focusing on recent important develo

149 However, differentiating cardiac amyloidosis from hypertrophic cardiomyopathy may

150 y, 256 patients diagnosed with transthyretin cardiac amyloidosis from March 2021 to March 2024 underw

151 No patient with light-chain cardiac amyloidosis had positive SPECT.

152 terization and bone scintigraphy to diagnose cardiac amyloidosis has revolutionized our understanding

153 most common form of hereditary transthyretin cardiac amyloidosis (hATTR-CA) in the United States and

154 About one-half of patients with ATTR cardiac amyloidosis have a history of carpal tunnel synd

155 at may be associated with thromboembolism in cardiac amyloidosis have not been defined.

156 h noninvasive diagnosis is possible for ATTR cardiac amyloidosis, histological demonstration and typi

157 sess the prevalence of sub-clinical isolated cardiac amyloidosis (ICA) at autopsy and the odds of AF

158 ognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and

159 e available for the 2 most frequent forms of cardiac amyloidosis: immunoglobulin light chain amyloido

160 magnetic resonance findings were of definite cardiac amyloidosis in 2, but could be explained solely

161 There were 4746 incident cases of cardiac amyloidosis in 2012 and 15 737 prevalent cases i

162 ging have resulted in greater recognition of cardiac amyloidosis in everyday clinical practice, but t

163 k to increase the suspicion of transthyretin cardiac amyloidosis in patients with heart failure.

164 l performs well in identifying patients with cardiac amyloidosis in the derivation cohort and all fou

165 erformed at 3 academic specialty centers for cardiac amyloidosis in the United States in which 229 pa

166 ore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap bet

167 Light chain cardiac amyloidosis, in particular, if recognized early

168 These include heart failure, cardiac amyloidosis, iron overload cardiomyopathy, hyper

169 ty for differentiation of patients with ATTR cardiac amyloidosis (irrespective of genotype) from pati

170 Cardiac amyloidosis is a differential diagnosis in heart

171 g a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than trad

172 Transthyretin-related cardiac amyloidosis is a progressive infiltrative cardio

173 Cardiac amyloidosis is a serious and progressive infiltr

174 Background Cardiac amyloidosis is a substantially underdiagnosed di

175 Hereditary transthyretin cardiac amyloidosis is an increasingly recognized cause

176 Cardiac amyloidosis is an infiltrative disease with dias

177 Cardiac amyloidosis is an underdiagnosed cause of infilt

178 Cardiac amyloidosis is associated with characteristic EC

179 Cardiac amyloidosis is associated with poor outcomes and

180 Cardiac amyloidosis is characterized by an early impairm

181 After the age of 60, isolated cardiac amyloidosis is four times more common among blac

182 Cardiac amyloidosis is increasingly recognized as a trea

183 Often considered a rare disease, cardiac amyloidosis is increasingly recognized by practi

184 reatments now available, timely diagnosis of cardiac amyloidosis is more important than ever.

185 Specific and accurate evaluation of cardiac amyloidosis is now possible using cardiac magnet

186 Sustained ventricular tachycardia (VT) in cardiac amyloidosis is uncommon, and the substrate and o

187 etin cardiac amyloidosis (also known as ATTR cardiac amyloidosis) is an increasingly recognized cause

188 tics of amyloid fibril formation of three AL cardiac amyloidosis light chains.

189 Cardiac amyloidosis may be an additional risk factor for

190 Manifestations of cardiac amyloidosis may include congestive heart failure

191 Both ATTRm and ATTRwt cardiac amyloidosis may manifest as heart failure (HF).

192 resonance was used to exclude patients with cardiac amyloidosis (n = 19).

193 (n=115), and coexisting AS and transthyretin cardiac amyloidosis (n=19) had a global ECV(CT) of 26.1

194 ients with definite amyloid light-chain (AL) cardiac amyloidosis (n=20; 100% with LVH).

195 severe diastolic dysfunction attributable to cardiac amyloidosis, n=9).

196 formed our ability to diagnose transthyretin cardiac amyloidosis noninvasively and unmasked a hithert

197 ective cohort of patients with transthyretin cardiac amyloidosis, older age was associated with lower

198 Cardiac amyloidosis patients and controls displayed simi

199 In conclusion, in treatment-naive, AL cardiac amyloidosis patients with heart failure symptoms

200 m 2018 (the first year covered) to 2022, and cardiac amyloidosis pyrophosphate scintigraphy studies i

201 e analyzed from 1217 patients with suspected cardiac amyloidosis referred for evaluation in specialis

202 sis of patients with suspected transthyretin cardiac amyloidosis referred for technetium-99 m pyropho

203 imilar area under the curve to transthyretin cardiac amyloidosis score (TCAS) (P=0.2); outperforming

204 as the published cut-offs for transthyretin cardiac amyloidosis score and septal apex to base (AUC:

205 ayo Clinic derived ATTR score (transthyretin cardiac amyloidosis score) were calculated.

206 hies that exhibit regional strain variation: cardiac amyloidosis, septal HCM, and apical HCM.

207 ased left ventricular wall thickness such as cardiac amyloidosis, septal hypertrophic cardiomyopathy

208 In light of these trends, cardiac amyloidosis should be considered during the init

209 ession analyses among participants with ATTR cardiac amyloidosis showed that an H/CL ratio of 1.6 or

210 Patients with primary (AL) cardiac amyloidosis suffer from progressive cardiomyopat

211 r whom there is a high clinical suspicion of cardiac amyloidosis, Tc 99m PYP may be of diagnostic and

212 In patients with cardiac amyloidosis, the pattern of LGE was always typic

213 trophic cardiomyopathy (HCM) and n = 28 with cardiac amyloidosis) undergoing a CMR scan were included

214 this review, we discuss molecular imaging of cardiac amyloidosis using amyloid PET tracers, including

215 s a major cause of cardiac dysfunction in AL cardiac amyloidosis, we have previously shown that amylo

216 ture and function and features suggestive of cardiac amyloidosis were assessed in participants who un

217 sis (AS) and coexisting AS and transthyretin cardiac amyloidosis were referred for a transcatheter ao

218 ic mechanisms underlying the pathogenesis of cardiac amyloidosis which have led to the development of

219 le method for identifying subjects with ATTR cardiac amyloidosis, which should be studied in a larger

220 We identified 156 patients with cardiac amyloidosis who underwent transesophageal echoca

221 and in patients with cardiac sarcoidosis and cardiac amyloidosis will also be described.

222 n and increasing incidence and prevalence of cardiac amyloidosis with advancing age, as well as the a

223 ivity and 92% specificity for detecting ATTR cardiac amyloidosis with an area under the curve of 0.96

224 f increased mortality in treatment-naive, AL cardiac amyloidosis with heart failure.